ArticleFrontiers in immunology2025
IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD25 (IL-2 receptor alpha chain) is a key component of the high-affinity receptor for the IL-2 cytokine and regulates the proliferation, survival, and differentiation of immune cells. The expression of CD25 has been demonstrated in basophils of patients with allergic diseases such as asthma. Previous studies have shown that IL-3 priming leads to increased CD25 expression in basophils. However, other potential stimuli that can regulate the CD25 expression on basophils and their possible biological consequences remain poorly understood. Here, we demonstrate that the IL-33 cytokine, a critical driver of type 2 immunity and allergic inflammation, significantly upregulates CD25 expression on IL-3-primed human basophils. Despite high levels of CD25 expression and its ability to capture IL-2 cytokine, basophils fail to express CD122 (IL-2 receptor beta chain), resulting in the absence of downstream signal transducer and activator of transcription 5 (STAT5) phosphorylation and lack of IL-2-mediated survival signals. The binding of IL-2 to basophil-derived CD25 appears to be transient since co-culturing with regulatory T cells (Treg cells) demonstrates that IL-2 remains accessible to Treg cells, enhancing their viability. Furthermore, an analysis of publicly available single-cell RNA sequencing data from COVID-19 patients revealed increased gene expressions of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.